Literature DB >> 32022405

Comorbidity of congenital heart defects and holoprosencephaly is likely genetically driven and gene-specific.

Cedrik Tekendo-Ngongang1, Babajide Owosela1, Maximilian Muenke1, Paul Kruszka1.   

Abstract

Comorbidity of holoprosencephaly (HPE) and congenital heart disease (CHD) in individuals with genetic variants in known HPE-related genes has been recurrently observed. Morphogenesis of the brain and heart from very early stages are regulated by several biological pathways, some of them involved in both heart and brain development as evidenced by genetic studies on model organisms. For instance, downregulation of Hedgehog or Nodal signaling pathways, both known as major triggers of HPE, has been shown to play a role in the pathogenesis of CHD, including structural defects and left-right asymmetry defects. In this study, individuals with various types of HPE were investigated clinically and by genomic sequencing. Cardiac phenotypes were assessed in 434 individuals with HPE who underwent targeted sequencing. CHDs were identified in 8% (n = 33) of individuals, including 10 (30%) cases of complex heart disease. Only four individuals (4/33) had damaging variants in the known HPE genes STAG2, SIX3, and SHH. Interestingly, no CHD was identified in the 37 individuals of our cohort with pathogenic variants in ZIC2. These findings suggest that CHD occurs more frequently in HPE-affected individuals with or without identifiable genetic variants, and this co-occurrence may be genetically driven and gene-specific.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  comorbidity; congenital heart disease; genomic sequencing; holoprosencephaly

Year:  2020        PMID: 32022405     DOI: 10.1002/ajmg.c.31770

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  1 in total

1.  Teratogenic effect of decitabine in a pregnant patient with acute myeloid leukemia: a case report.

Authors:  Bee Sun Lee; Jameela Sathar; Tee Chuan Ong
Journal:  Hematol Transfus Cell Ther       Date:  2020-12-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.